Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New device aims to speed up finger nerve healing

NCT ID NCT07524465

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 25, 2026 · Updated 3 times

Summary

This study is testing a device called ReFeel, which is used to repair damaged nerves in the fingers. The goal is to see if it helps people recover faster and with better results, like improved feeling and less pain. Only 5 adults with a specific type of finger nerve injury will be observed for up to 12 months after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ReFeel device (a nerve repair device)
What this could lead to
If successful, this could point toward a better way to repair damaged nerves in fingers, potentially improving sensation and reducing pain.
What could go wrong
This is a very small study (only 5 people) and is observational, so results may not apply widely. The device is already approved, but its effectiveness for digital nerves is still being tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 5 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 69 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-69 years * Digital nerve injury in at least one digit requiring repair with a gap of 1-25mm * Able to provide tension free end to end nerve coaptation * Have uninjured contralateral or adjacent digit that is suitable to serve as a referenced digit for baseline functional assessments. * Willing to comply with follow up for visits up to 12 months. Exclusion Criteria: * Estimated distance of recovery greater than 150 mm (from proximal site of to the tip of the digit) * Injury distal to distal interphalangeal joint * Extensive soft tissue injury that will impair recovery assessment * Incomplete nerve transections * Injury requiring replantation of the target digit * Injuries to the affected nerve proximal to the superficial arch * Nerve injuries \> 24 weeks after initial injury * End to side nerve repair * Injuries with vascular damage resulting in inadequate perfusion despite repair * Subjects with type 1 diabetes or type 2 diabetes requiring regular insulin therapy * Subjects who are undergoing or expected to undergo treatment with chemotherapy, radiation therapy, or other know treatment that affects the growth of neural and/or vascular system * History of neuropathy, diabetic neuropathy, or another known neuropathy * Excepted use of medication during the study that is known to impact nerve regeneration or cause peripheral neuropathy such as immunosuppressant's and Chemotherapeutic * History of chronic ischemic condition of the upper extremity. * Workers Compensation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Digital nerve injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • OrthoCarolina Research Institute

    Charlotte, North Carolina, 28207, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.